Adagio Therapeutics to Participate in the Guggenheim 2nd Annual Vaccines & Infectious Day Conference

Rhea-AI Summary

Adagio Therapeutics (Nasdaq: ADGI) will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Disease Conference on Oct. 6, 2021, at 1:30 p.m. ET. The event will be streamed live on the investor section of their website and archived for 60 days. Adagio focuses on developing antibody-based solutions for infectious diseases with pandemic potential. Their antibody portfolio, including ADG20, aims to offer broad neutralization against SARS-CoV-2, enhanced manufacturability, and affordability.

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that management will participate in a fireside chat during the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on Wednesday, Oct. 6, 2021 at 1:30 p.m. ET.

The live webcast will be available in the investor section of the company's website at investors.adagiotx.com. The webcast will be archived for 60 days following the presentation.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

FAQ

When is Adagio Therapeutics participating in the Guggenheim Conference?

Adagio Therapeutics will participate in the Guggenheim 2nd Annual Vaccines & Infectious Disease Conference on Oct. 6, 2021, at 1:30 p.m. ET.

Where can I watch the Adagio Therapeutics conference webcast?

The webcast for Adagio's participation in the conference will be available on their investor website at investors.adagiotx.com.

What is the focus of Adagio Therapeutics?

Adagio Therapeutics focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential.

What is ADG20?

ADG20 is a broadly neutralizing antibody developed by Adagio Therapeutics, designed to target SARS-CoV-2 and provide durable protection.

How long will the Adagio webcast be available after the presentation?

The Adagio webcast will be archived for 60 days following the presentation.